SALARIUS PHARMACEUTICALS INC (SLRX)

US79400X3052 - Common Stock

0.53  +0.04 (+8.16%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

SALARIUS PHARMACEUTICALS INC

NASDAQ:SLRX (3/28/2024, 4:10:55 PM)

0.53

+0.04 (+8.16%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap2.09M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

SLRX Daily chart

Company Profile

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. The company is headquartered in Houston, Texas and currently employs 12 full-time employees. The company went IPO on 2015-01-29. The firm is focused on developing effective treatments for cancers with unmet medical needs. The company is developing treatments for cancers caused by dysregulated gene expression. The Company’s product portfolio includes seclidemstat, which is being studied as a potential treatment for pediatric cancers, sarcomas and other cancers with limited treatment options. The firm's pipeline consists of two primary compounds: SP-3164, a small-molecule protein degrader, and seclidemstat (SP-2577), a small-molecule inhibitor. SP-3164 is a next-generation cereblon-binding molecular glue (MG). SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold. The molecule was discovered using structure-based computational screening coupled with chemical screening.

Company Info

SALARIUS PHARMACEUTICALS INC

2450 Holcombe Blvd Ste J-608

Houston TEXAS 77021

P: 13467720346

CEO: David J. Arthur

Employees: 12

Website: https://salariuspharma.com/

SLRX News

News Image2 days ago - ChartmillThese stocks have an unusual volume in today's session

Let's explore the current happenings on the US markets on Tuesday. Below, you'll find the stocks exhibiting unusual volume in today's session.

News Image3 days ago - BusinessInsiderWhy Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket

Shares of Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) rose sharply in today’s pre-market trading following fourth-quarter results.

News Image3 days ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We are starting off the day with a breakdown of the biggest pre-market stock movers that traders need to know about on Monday morning.

News Image6 days ago - InvestorPlaceSLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q4 2023

SLRX stock results show that Salarius Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023.

News Image6 days ago - BusinessInsiderSLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Salarius Pharmaceuticals (NASDAQ:SLRX) just reported results for the fourth qua...

News Image6 days ago - Salarius Pharmaceuticals, Inc.Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Patient Enrollment Resumed in the Investigator-initiated Phase 1/2 Clinical Trial of Seclidemstat in Combination with Azacitidine to Treat Hematologic...

SLRX Twits

Here you can normally see the latest stock twits on SLRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example